AI
| Followers | 144 |
| Posts | 28003 |
| Boards Moderated | 4 |
| Alias Born | 02/07/2004 |
Thursday, December 31, 2020 10:35:15 AM
RedHill posts positive data from phase 2 COVID-19 study of Opaganib
Dec. 31, 2020 10:11 AM ETRedHill Biopharma Ltd. (RDHL)By: Aakash Babu, SA News Editor
RedHill Biopharma (RDHL +3.2% announces preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.
The study aimed to evaluate safety and identify preliminary signs of activity. Patients in the study were randomized at a 1:1 ratio to receive either Opaganib or placebo on top of standard-of-care ((SoC)) and were followed up for up to 42 days post treatment initiation.
Full analysis of the data, including viral and inflammatory biomarker analyses, baseline risk factors and SoC background therapy stratifications, is expected in the coming weeks.
Top-line data from the global Phase 2/3 COVID-19 study in 270 hospitalized patients is expected in Q1 of 2021.
"We continue to work diligently to compile a robust data set to support potential filing of global emergency use applications," Mark Levitt, Medical Director at RedHill said.
------------------------------------------------------------------
Well, at least they kept their promise to publish results
before years end
Dec. 31, 2020 10:11 AM ETRedHill Biopharma Ltd. (RDHL)By: Aakash Babu, SA News Editor
RedHill Biopharma (RDHL +3.2% announces preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.
The study aimed to evaluate safety and identify preliminary signs of activity. Patients in the study were randomized at a 1:1 ratio to receive either Opaganib or placebo on top of standard-of-care ((SoC)) and were followed up for up to 42 days post treatment initiation.
Full analysis of the data, including viral and inflammatory biomarker analyses, baseline risk factors and SoC background therapy stratifications, is expected in the coming weeks.
Top-line data from the global Phase 2/3 COVID-19 study in 270 hospitalized patients is expected in Q1 of 2021.
"We continue to work diligently to compile a robust data set to support potential filing of global emergency use applications," Mark Levitt, Medical Director at RedHill said.
------------------------------------------------------------------
Well, at least they kept their promise to publish results
before years end
